Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999777 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT01999777 is a Phase 3 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 62 participants.
The verdict
NCT01999777, a Phase 3 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.
Interventions
- DRUG Placebo
- DRUG USL261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999777
The ClinicalTrials.gov registry entry for NCT01999777 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01999777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999777 about?
NCT01999777 is a clinical study titled "Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU". This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.
What is the current status of trial NCT01999777?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2013-11. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01999777?
The interventions under investigation include: Placebo (DRUG), USL261 (DRUG).
Who is sponsoring clinical trial NCT01999777?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.